Ivax — Merger or Acquisition (July 2005)
15 slides from Ivax's merger presentation, Jul 26, 2005
Slide 1: Pharmaceutical Industries Ltd. July 2005
Pharmaceutical Industries Ltd. July 2005
Slide 2: Forward-looking statements
TODAY'S PRESENTATION CONTAINS FORWARD LOOKING STATEMENTS WHICH EXPRESS THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT. SUCH STATEMENTS ARE BASED ON CURRENT EXPECTATIONS AND INVOLVE A NUMBER OF KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES THAT COULD CAUSE TEVA'S FUTURE RESULTS, PERFORMANCE OR ACHIEV
Slide 3: Teva Acquisition of Ivax
Teva Acquisition of Ivax Transaction Overview Strategic Rationale Financial Benefits Complementary Businesses, Geographies and Technologies A Leading Generic Company Summary
Slide 4: Transaction Overview
Transaction Overview Teva to acquire Ivax for approximately $7.4 billion Teva to assume Ivax's existing debt (approximately $1B) Financed with a combination of equity, debt and cash Combination brings together complementary products, pipelines and geographies enhancing growth opportunities Direct pr
Slide 5: Strategic Rationale
Strategic Rationale Enhances leadership position in the US, expands strong presence in Europe and significantly boosts reach in Latin America Brings together exciting prospects for growth, with new proprietary drug offerings in key therapeutic areas including Respiratory (Ivax), Central Nervous Syst
Slide 6: Financial Benefits
Financial Benefits Transaction expected to become accretive to earnings within first year after closing Ample opportunities for synergies of up to $150 million by the end of the second year after closing Synergies will come from efficiencies in manufacturing, SG&A and R&D Consolidation of operations
Slide 7: Complementary Businesses: 2004 Revenue Contribution Analysis
Teva - $4,799 million Ivax - $1,837 million Pro Forma - $6,636 million 2004 Revenue by Product Type ($ in millions) + = ($ in millions) Complementary Businesses 2004 Revenue Contribution Analysis Figures are based on publicly available information
Slide 8: Complementary Geographies
Complementary Geographies Strengthens leadership in US generics Portfolio Pipeline Technologies Enhances current leadership position in the UK Obtains leadership position in France, Russia and Czech Republic and gains strong base in Poland Builds leading presence in Latin America including Venezuela
Slide 9: Complementary Geographies: Revenue by Geography
Teva - $4,799 million Ivax - $1,880 million(1) Pro Forma - $6,679 million(1) 2004 Revenue by Geography + = ($ in millions) Excludes $42.1 million in Ivax corporate overhead and other expenses Figures are based on external reporting published by each company respectively Complementary Geographies
Slide 10: Complementary Technologies
Complementary Technologies Combined technology coverage includes Tablets Capsules Controlled release Ointments Creams Liquids Suspensions Soft gels Injectibles Metered dose inhalers Nasal sprays Breath actuated inhalers Breath operated inhalers
Slide 11: Global Generic Research & Development
Global Generic Research & Development Value in combined pipeline Increased filings at FDA Complementary therapeutic areas Increased likelihood of first to file (FTF) Shared broad line philosophy Strong scientific capabilities and technology across markets and geographies Opportunities to leverage de
Slide 12: Expanded Therapeutic Proprietary Portfolio
Expanded Therapeutic Proprietary Portfolio Ivax Respiratory Unique breath-operated inhaler technology Environmentally friendly inhalers Oncology Extensive pipeline Nine products in various stages of clinical development Other products in pre-clinical development Neurology MS Epilepsy Teva MS Copaxon
Slide 13: Financial Terms of the Transaction
Financial Terms of the Transaction Purchase consideration $26 per Ivax share, via cash election merger, comprised of $26 in cash or 0.8471 Teva shares (total consideration: $7.4B for stock and approximately $1B for Ivax's debt) Form of consideration subject to proration, based on Ivax shareholders'
Slide 14: Summary
Summary Combination strengthens global leadership in generics, adds new product lines and growth markets Transaction brings together businesses with complementary geographies, products and pipelines Creates cost and sales synergies in generics and innovative businesses and increased vertical integra
Slide 15: Pharmaceutical Industries Ltd. July 2005
Pharmaceutical Industries Ltd. July 2005